Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03041688
Title Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Los Angeles General Medical Center Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Keck Medical Center of USC Pasadena Pasadena California 91105 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 United States Details
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 United States Details
Brigham and Women's Hospital Boston Massachusetts 02115 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
Virginia Commonwealth University/Massey Cancer Center Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field